- Previous Close
33.000 - Open
32.500 - Bid 28.700 x --
- Ask 28.750 x --
- Day's Range
28.600 - 32.500 - 52 Week Range
12.080 - 33.600 - Volume
63,512,388 - Avg. Volume
4,828,903 - Market Cap (intraday)
34.389B - Beta (5Y Monthly) --
- PE Ratio (TTM)
54.15 - EPS (TTM)
0.530 - Earnings Date Mar 25, 2025 - Apr 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.56
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
wuxixdc.com1,496
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 2268.HK
View MorePerformance Overview: 2268.HK
Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2268.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2268.HK
View MoreValuation Measures
Market Cap
39.54B
Enterprise Value
35.92B
Trailing P/E
62.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.33
Price/Book (mrq)
6.22
Enterprise Value/Revenue
12.11
Enterprise Value/EBITDA
47.67
Financial Highlights
Profitability and Income Statement
Profit Margin
21.27%
Return on Assets (ttm)
7.18%
Return on Equity (ttm)
15.46%
Revenue (ttm)
2.8B
Net Income Avi to Common (ttm)
594.55M
Diluted EPS (ttm)
0.530
Balance Sheet and Cash Flow
Total Cash (mrq)
3.48B
Total Debt/Equity (mrq)
1.15%
Levered Free Cash Flow (ttm)
-945.69M